Year of publication
- 2003 (2) (remove)
- English (2) (remove)
- Production of recombinant human endothelin B receptor in different hosts and its subsequent solubilization and purification (2003)
- The endothelin B receptor belongs to the rhodopsin-like G-protein coupled receptors family. It plays an important role in vasodilatation and is found in the membranes of the endothelial cells enveloping blood vessels. During the course of this work, the production of recombinant human ETB receptor in yeast, insect and mammalian cells was evaluated. A number of different receptor constructs for production in the yeast P. pastoris was prepared. Various affinity tags were appended to the receptor N-and C-termini to enable receptor detection and purification. The clone pPIC9KFlagHisETBBio, with an expression level of 60 pmol/mg, yielded the highest amount of active receptor (1.2 mg of receptor per liter of shaking culture). The expression level of the same clone in fermentor culture was 17 pmol/mg, and from a 10L fermentor it was possible to obtain 3 kg of cells that contained 20-39 mg of the receptor. For receptor production in insect cells, Sf9 (S. frugiperda) suspension cells were infected with the recombinant baculovirus pVlMelFlagHisETBBio. The peak of receptor production was reached at 66 h post infection, and radioligand binding assays on insect cell membranes showed 30 pmoL of active receptor /mg of membrane protein. Subsequently, the efficiency of different detergents in solubilizing the active receptor was evaluated. N-dodecyl-beta-D-maltoside (LM), lauryl-sucrose and digitonine/cholate performed best, and LM was chosen for further work. The ETB receptor was produced in mammalian cells using the Semliki Forest Virus expression system. Radioligand binding assays on membranes from CHO cells infected with the recombinant virus pSFV3CAPETBHis showed 7 pmol of active receptor /mg of membrane protein. Since the receptor yield from mammalian cells was much lower than in yeast and insect cells, this system was not used for further large-scale receptor production. After production in yeast and insect cells, the ETB receptor was saturated with its ligand, endothelin-1, in order to stabilize its native form. The receptor was subsequently solubilized with n-dodecyl-beta-D-maltoside and subjected to purification on various affinity matrices. Two-step affinity purification via Ni2+-NTA and monomeric avidin proved the most efficient way to purify milligram amounts of the receptor. The purity of the receptor preparation after this procedure was over 95%, as judged from silver stained gels. However, the tendency of the ETB receptor produced in yeast to form aggregates was a constant problem. Attempts were made to stabilize the active, monomeric form of the receptor by testing a variety of different buffer conditions, but further efforts in this direction will be necessary in order to solve the aggregation problem. In contrast to preparations from yeast, the purification of the ETB receptor produced in insect cells yielded homogeneous receptor preparations, as shown by gel filtration analysis. This work has demonstrated that the amounts of receptor expressed in yeast and insect cells and the final yield of receptor, isolated by purification, represent a good basis for beginning 3D and continuing 2D crystallization trials.
- Regulation of IL-18 binding protein by IFN-gamma (2003)
- In this study we investigated the regulation of IL-18BPa by IFN-y in the context of colon cancer and human autoimmune diseases. IL-18BPa is a naturally occuring inhibitor that counteracts IL-18 bioactivity. By enhancing IFN-y production IL-18 has been introduced as pivotal mediator of TH1 immune responses. Indeed, many IL-18 effects are mediated by IFN-y. IL-18 bioactivity is connected with the pathogenesis of different inflammatory diseases, for instance, septic shock, colitis, Crohn's disease, myasthenia gravis, multiple sclerosis, rheumatoid arthritis, atherosclerosis, and organ transplant rejection. In addition, IL-18 has tumor-suppressive properties. IFN-y induced IL-18BPa expression was shown on protein and mRNA level in different colon carcinoma cell lines, organ cultures of colonic intestinal biopsy specimens, HaCaT keratinocytes as well as rheumatoid arthritis fibroblastlike synoviocytes (RA-FLS). The IFN-y-mediated induction of IL-18BPa appears to be a more general phenomenom. The capability of IFN-y to induce IL-18BPa also has been confirmed on the promoter level by performing luciferase reporter gene studies with two IL- 18BP promoter fragments. A GAS-site proximal to the transcription start site has been identified to be relevant for IFN-y-mediated induction of these two IL18BP promoter fragments. The induction of IL-18BPa is most likely mediated by STAT-1 in DLD-1 colon carcinoma cells. Sodium butyrate inhibited IFN-y-induced IL-18BPa expression in these cells. On the basis of our observations, we postulate a negative feedback mechanism, by which IFN-y-dependent and -independent IL-18 action might be counterregulated. In this model sodium butyrate is an additional player, that may interrupt the postulated negative feedback loop. A coculture system was performed to simulate an inflammatory TH1 response. This model which is more close to the in vivo situation, confirmed upregulation of IL-18BPa by endogenously produced IFN-y. The role of IL-18BPa is manifold and depends on IL-18 function in each particular case. In autoimmune diseases, for instance, which are often characterized by a TH1 polarized immune response, IL-18BPa might counterregulate IL-18 and/or IL-18-induced IFN-y bioactivity. Important examples are Crohn's disease and rheumatoid arthritis. In CD therapeutic use of IL-18BPa may therefore restore a hypothetically disturbed IL-18/IL-18BP balance. Concerning RA, IL-18BPa expression might contribute to protective functions of IFN-y, observed in different murine models for arthritis and in rheumatoid arthritis patients. Moreover, IL-18BPa might inhibit IL-18-mediated induction of subsequent cardinal inflammatory cytokines responsible for the pathogenesis of these diseases. Indeed, the pharmaceutical industry successfully used IL-18BP as therapeutic agent in a murine model of RA and in phase I clinical trials. On the contrary, in the context of carcinogenesis IFN-y- mediated IL-18BPa expression might be disadvantageous. By counterregulating the IL-18 arm of immune defenses against tumors, IL-18BP may have the potential to promote carcinogenesis. Our hypothesis is underlined by the observation that sodium butyrate, known to be protective in colon cancer, inhibited IFN-y-induced IL-18BPa expression. In parallel, IL-18-induced IFN-y is also responsible for iNOS induction. iNOS-derived NO provides a second possible way for inhibition of IFN-y-dependent and -independent tumor suppressive effects of IL-18. Finally, IFN-y-induced IL-18BPa expression was confirmed on the promoter level. This induction on the promoter level was associated with STAT-1 binding to the GAS element proximal to the start of transcription. It is tempting to speculate that blockage of the cytokine cascade upstream of IL-1 and TNF- a on the level of IL-18 may be of therapeutic benefit. Our data reflect the relationship between inflammation and cancer, in that inflammatory cells and cytokines found in tumors are likely to contribute to tumor growth, progression, and immunosuppression than they are to mount an effective host antitumour response.